Redeye initiates coverage of Mentice, a medtech company expanding its TAM many times over through vertical integration from endovascular simulation to IGIT performance solutions. We judge today’s share price represents an attractive entry opportunity for long-term-oriented investors should Mentice achieve its sales growth targets and improve its profitability.

Read more and download the Research Report.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

Attachments

Redeye Initiates Coverage of Mentice

© Modular Finance, source Nordic Press Releases